Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

As of July 18, 2025, the Food and Drug Administration (FDA) said it has received three reports of fatal acute liver failure ...

U.S. stocks ended the week mostly higher, with the S&P 500 (+0.6%) and Nasdaq (+1.5%) setting new record highs, lifted by strong Q2 earnings and softer-than-expected inflation data. June retail sales ...

The FDA called for Sarepta Therapeutics to stop shipping its muscular dystrophy gene therapy, but the company said no.

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...